Literature DB >> 16003810

Biocatalytic approaches to hetero-Diels-Alder adducts of carbonyl compounds.

Véronique Gouverneur1, Maud Reiter.   

Abstract

Very little information is available on hetero-Diels-Alderases for the assembly of heterocyclic products despite the synthetic value of these [4+2] cycloadditions. Hetero-Diels-Alderase antibodies raised against a bicyclic transition state analogue have been generated for the cycloaddition of ethylglyoxylate with an all-carbon diene. More recently, a conceptually novel biocatalytic approach to hetero-Diels-Alder (HDA) adducts derived from carbonyl dienophiles has been developed mirroring a stepwise aldol Michael mechanism instead of a concerted pathway. In this approach, the two key steps are an antibody-mediated kinetic resolution of beta-hydroxyenones and a subsequent ring-closure process. An attractive feature of this methodology is the possibility to convert the enantioenriched aldol intermediates into tetrahydropyranones or dihydropyranones. This bioorganic route is best applied for the preparation of enantioenriched HDA adducts derived from poorly electrophilic acceptors, therefore complementing existing catalytic routes to these adducts based on the use of small organocatalysts or chiral Lewis acids.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16003810     DOI: 10.1002/chem.200500406

Source DB:  PubMed          Journal:  Chemistry        ISSN: 0947-6539            Impact factor:   5.236


  2 in total

1.  Catalytic enantioselective hetero-Diels-Alder reactions of an azo compound.

Authors:  Masanori Kawasaki; Hisashi Yamamoto
Journal:  J Am Chem Soc       Date:  2006-12-27       Impact factor: 15.419

2.  Simple organocatalyst component system for asymmetric hetero Diels-Alder reaction of isatins with enones.

Authors:  Perumalsamy Parasuraman; Zubeda Begum; Madhu Chennapuram; Chigusa Seki; Yuko Okuyama; Eunsang Kwon; Koji Uwai; Michio Tokiwa; Suguru Tokiwa; Mitsuhiro Takeshita; Hiroto Nakano
Journal:  RSC Adv       Date:  2020-05-05       Impact factor: 4.036

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.